These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22258374)

  • 21. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
    Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for Prostate Cancer.
    Venturini NJ; Drake CG
    Cold Spring Harb Perspect Med; 2019 May; 9(5):. PubMed ID: 30201787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
    Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
    Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
    Parente P; Parnis F; Gurney H
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in prostate cancer: review of the current evidence.
    Fernández-García EM; Vera-Badillo FE; Perez-Valderrama B; Matos-Pita AS; Duran I
    Clin Transl Oncol; 2015 May; 17(5):339-57. PubMed ID: 25480118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer].
    Omlin A; Gillessen S
    Urologe A; 2012 Jan; 51(1):8-14. PubMed ID: 22258370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and emerging treatments in the management of castration-resistant prostate cancer.
    Shapiro D; Tareen B
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
    Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New agents for the management of castration-resistant prostate cancer.
    Cersosimo RJ
    Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer.
    Kittai A; Meshikhes M; Aragon-Ching JB
    Cancer Biol Ther; 2014 Oct; 15(10):1299-300. PubMed ID: 25046606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ; Zhang J
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
    van Dodewaard-de Jong JM; Verheul HMW; Bloemendal HJ; de Klerk JMH; Carducci MA; van den Eertwegh AJM
    Clin Genitourin Cancer; 2015 Aug; 13(4):271-279. PubMed ID: 25704270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.